Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 92.68 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $50.025 million which beat the analyst consensus estimate of $48.607 million by 2.92 percent. This is a 613.22 percent increase over sales of $7.014 million the same period last year.
Avadel Pharmaceuticals Q3 2024 GAAP EPS $(0.03) Beats $(0.06) Estimate, Sales $50.025M Beat $48.607M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated